2. Academic Validation
  3. CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia

CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia

  • J Transl Med. 2024 Mar 13;22(1):274. doi: 10.1186/s12967-024-04990-6.
Na Yang 1 2,  Caili Zhang 1,  Yingchun Zhang 3,  Yuting Fan 1 2,  Jing Zhang 3,  Xiaojin Lin 1 3,  Ting Guo 4,  Yangzuo Gu 5,  Jieheng Wu 2,  Jianmei Gao 6,  Xing Zhao 7 8 9,  Zhixu He 10 11 12 13
Affiliations

Affiliations

  • 1 Tissue Engineering and Stem Cell Experiment Center, Guizhou Medical University (GMU), Guiyang, Guizhou, China.
  • 2 Department of Immunology, College of Basic Medical Sciences, Guizhou Medical University, Guiyang, Guizhou, China.
  • 3 Department of Biology, School of Basic Medical Sciences, Guizhou Medical University, Guiyang, Guizhou, China.
  • 4 Department of Gynecology, the Affiliated Hospital of Guizhou Medical University, Guiyang, China.
  • 5 State Key Laboratory of Biotherapy and Cancer Center, Sichuan University, Chengdu, China.
  • 6 School of Pharmacy, Zunyi Medical University, Zunyi, China.
  • 7 Tissue Engineering and Stem Cell Experiment Center, Guizhou Medical University (GMU), Guiyang, Guizhou, China. xingzhao@gmc.edu.cn.
  • 8 Department of Immunology, College of Basic Medical Sciences, Guizhou Medical University, Guiyang, Guizhou, China. xingzhao@gmc.edu.cn.
  • 9 Department of Biology, School of Basic Medical Sciences, Guizhou Medical University, Guiyang, Guizhou, China. xingzhao@gmc.edu.cn.
  • 10 Tissue Engineering and Stem Cell Experiment Center, Guizhou Medical University (GMU), Guiyang, Guizhou, China. zxhe@zmu.edu.cn.
  • 11 Department of Immunology, College of Basic Medical Sciences, Guizhou Medical University, Guiyang, Guizhou, China. zxhe@zmu.edu.cn.
  • 12 Key Laboratory of Adult Stem Cell Translational Research, Chinese Academy of Medical Sciences), Guiyang, China. zxhe@zmu.edu.cn.
  • 13 Department of Pediatrics, the Affiliated Hospital of Zunyi Medical University, Zunyi, China. zxhe@zmu.edu.cn.
PMID: 38475814 DOI: 10.1186/s12967-024-04990-6
Abstract

Background: Chimeric antigen receptor natural killer (CAR-NK) cells represent a promising advancement in CAR cell therapy, addressing limitations observed in CAR-T cell therapy. However, our prior study revealed challenges in CAR-NK cells targeting CD19 antigens, as they failed to eliminate CD19+ Raji cells in NSG tumor-bearing mice, noting down-regulation or loss of CD19 antigen expression in some Raji cells. In response, this study aims to enhance CD19 CAR-NK cell efficacy and mitigate the risk of tumor recurrence due to target antigen escape by developing CD19 and CD20 (CD19/CD20) dual-targeted CAR-NK cells.

Methods: Initially, mRNA encoding anti-CD19 CARs (FMC63 scFv-CD8α-4-1BB-CD3ζ) and anti-CD20 CARs (LEU16 scFv-CD8α-4-1BB-CD3ζ) was constructed via in vitro transcription. Subsequently, CD19/CD20 dual-targeted CAR-NK cells were generated through simultaneous electrotransfection of CD19/CD20 CAR mRNA into umbilical cord blood-derived NK cells (UCB-NK).

Results: Following co-electroporation, the percentage of dual-CAR expression on NK cells was 86.4% ± 1.83%, as determined by flow cytometry. CAR expression was detectable at 8 h post-electric transfer, peaked at 24 h, and remained detectable at 96 h. CD19/CD20 dual-targeted CAR-NK cells exhibited increased specific cytotoxicity against acute lymphoblastic leukemia (ALL) cell lines (BALL-1: CD19+CD20+, REH: CD19+CD20-, Jurkat: CD19-CD20-) compared to UCB-NK, CD19 CAR-NK, and CD20 CAR-NK cells. Moreover, CD19/CD20 dual-targeted CAR-NK cells released elevated levels of perforin, IFN-γ, and IL-15. Multiple activation markers such as CD69 and cytotoxic substances were highly expressed.

Conclusions: The creation of CD19/CD20 dual-targeted CAR-NK cells addressed the risk of tumor escape due to antigen heterogeneity in ALL, offering efficient and safe 'off-the-shelf' cell products. These cells demonstrate efficacy in targeting CD20 and/or CD19 antigens in ALL, laying an experimental foundation for their application in ALL treatment.

Keywords

Acute lymphoblastic leukemia; Chimeric antigen receptor; Dual targets; Natural killer cells; mRNA.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z